Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom
- PMID: 8091854
- DOI: 10.1016/0264-410x(94)90227-5
Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom
Erratum in
- Vaccine 1994 Oct;12(13):1248
Abstract
Four vaccines are available in the United Kingdom against influenza virus. All are subunit vaccines, defined as either split-virion or purified surface antigen vaccine; there are two of each distinct type available. Both vaccine types are less reactogenic than whole inactivated virus, with antigenicity induced by viral surface glycoproteins. Here, each of the four vaccines has been characterized by electron microscopy and SDS-PAGE analysis, giving a unique vaccine profile. Three vaccines contain internal viral nucleoprotein which, in the presence of residual haemagglutinin, may induce an influenza A virus cross-reactive cytotoxic T-cell response and thus be of value to vaccine efficacy. Residual lipid was present in three vaccines and recent evidence suggests that pyrogenicity is correlated with the presence of viral lipid with clusters of surface glycoproteins. By a combination of electron microscopic evidence and biochemical characterization, it has been possible to resolve compositional differences, not only between vaccine type, but also between each individual currently available vaccine. Hence, there is the possibility that the morphological differences characterized here may be contributory to potential reactogenic effects subsequent to vaccination.
Similar articles
-
Comparative analysis of six European influenza vaccines.Eur J Clin Microbiol Infect Dis. 1996 Feb;15(2):121-7. doi: 10.1007/BF01591484. Eur J Clin Microbiol Infect Dis. 1996. PMID: 8801083
-
Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins.J Gen Virol. 1992 Jun;73 ( Pt 6):1345-54. doi: 10.1099/0022-1317-73-6-1345. J Gen Virol. 1992. PMID: 1607857
-
[Control of subunit influenza vaccines].Ann Ist Super Sanita. 1989;25(2):333-6. Ann Ist Super Sanita. 1989. PMID: 2589734 Italian.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
-
[Iscom (Immuno Stimulating Complex)-vaccine of equine influenza virus--transmission electron microscopic investigation and literature review].Dtsch Tierarztl Wochenschr. 1997 Jun;104(6):196-202. Dtsch Tierarztl Wochenschr. 1997. PMID: 9303851 Review. German.
Cited by
-
Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.Drugs Aging. 1995 May;6(5):368-87. doi: 10.2165/00002512-199506050-00004. Drugs Aging. 1995. PMID: 7647426
-
Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3330-5. doi: 10.1073/pnas.0813309106. Epub 2009 Feb 11. Proc Natl Acad Sci U S A. 2009. PMID: 19211791 Free PMC article.
-
Comparative analysis of six European influenza vaccines.Eur J Clin Microbiol Infect Dis. 1996 Feb;15(2):121-7. doi: 10.1007/BF01591484. Eur J Clin Microbiol Infect Dis. 1996. PMID: 8801083
-
Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.PLoS One. 2012;7(12):e50830. doi: 10.1371/journal.pone.0050830. Epub 2012 Dec 11. PLoS One. 2012. PMID: 23239987 Free PMC article.
-
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019. NPJ Vaccines. 2019. PMID: 30701093 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical